Aura Biosciences, Inc. (AURA)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-11) · 99.1 · 99.2 | 8-K (2026-05-04) | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-30) · 99.1 · 99.2 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-13) · 99.1 · 99.2 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-13) · 99.1 · 99.2 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-15) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-24) · 99.1 · 99.2 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-12) · 99.1 · 99.2 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-08) · 99.1 · 99.2 | ||
| 10-K/A | FY-2023 | |||
| 10-Q | Q1-2024 | 8-K (2024-05-09) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-27) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-09) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-09) · 99.1 · 99.2 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Stockholders' Equity (P) | ||
| Notes | ||
| Accrued Expenses and Other Current Liabilities | ||
| Commitment and Contingencies | ||
| Common Stock Warrants | ||
| Compensation | ||
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Description of Business | ||
| Equity | ||
| Fair Value of Assets and Liabilities | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Marketable Securities | ||
| Net Loss Per Share | ||
| Pay Vs Performance Disclosure | ||
| Prepaid Expenses and Other Current Assets | ||
| Property and Equipment, Net | ||
| Segment Reporting | ||
| Stock-based Compensation | ||
| Stockholders' Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||
| Warrants | ||